Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 0357 • ACR Convergence 2023
Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting
Pamela F. Weiss¹, Nicolino Ruperto², Erhard Quebe-Fehling³, Alexis Shew⁴, Luminita Pricop⁵, Christelle Pieterse³ and Hermine Brunner⁶, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, St. Louis, MO, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: The juvenile spondyloarthritis disease activity index (JSpADA) is a disease activity assessment tool developed for children with juvenile psoriatic arthritis (JPsA) and enthesitis related…
Abstract Number: 0377 • ACR Convergence 2023
Disease Activity and New Medication Start at Two Consecutive Registry Visits for Patients with Juvenile Idiopathic Arthritis
Melissa Mannion¹, Monica Aswani², Kristine Hearld², Emily Smitherman², Livie Huie³ and Jeffrey R Curtis⁴, ¹University of Alabama at Brimingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Gardendale, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL
Background/Purpose: The goal of treatment for patients with juvenile idiopathic arthritis (JIA) is inactive or minimal disease activity and escalating medication for active disease is…
Abstract Number: 1658 • ACR Convergence 2023
Title: Inflammatory Arthritis Across the Age-Spectrum: Single-Cell Profiling of the Inflamed Synovium in Children with Juvenile Idiopathic Arthritis
Chrissy Bolton¹, Christopher Mahony², Charlotte Smith², Vicky Alexiou³, Huong Nguyen³, Patricia Reis-Nisa², Søren Lomholt⁴, Annie Hackland², Sugrah Sultan⁵, Klaudia Kupiec³, Sunit Davda⁶, Charlene Foley⁶, Calliope Dendrou¹, Elizabeth C Rosser⁷, Accelerating Medicines Partnership Program RA SLE Network⁸, Anna Helena Jonsson⁹, Fan Zhang¹⁰, Michael Brenner¹¹, Soumya Raychaudhuri⁹, Christopher Buckley¹, Manigandan Thyagarajan⁵, Zishan Shiekh⁵, Sandrine Compeyrot-Lacassagne⁶, Samantha Chippington⁶, Mark Coles¹, Eslam Al-Abadi⁵, Andrew Filer², Tissue Research in Childhood Onset Inflammatory Arthritis (TRICIA) Consortium¹², Lucy R Wedderburn³ and Adam Croft², ¹University of Oxford, Oxford, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³UCL Great Ormond Street Institute of Child Health, London, United Kingdom, ⁴Aarhus University, Aarhus, Denmark, ⁵Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, ⁶Great Ormond Street Hospital, London, United Kingdom, ⁷University College London, London, United Kingdom, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰University of Colorado, Aurora, CO, ¹¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²MRC, Birmingham, United Kingdom
Background/Purpose: Understanding the unique and shared pathogenic processes between childhood-onset and adult-onset inflammatory arthritides is needed to guide more effective drug development and their application…
Abstract Number: 095 • 2023 Pediatric Rheumatology Symposium
Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe
Claudia Bracaglia¹, Francesca Minoia², Christoph Kessel³, Sebastiaan Vastert⁴, Manuela Pardeo¹, Alessia Arduini¹, Sarka Fingerhutova⁵, Irina Nikishina⁶, Ozge Basaran⁷, Nural Kiper⁸, Mikhail Kostik⁹, Mia Glerup¹⁰, Roberta Caorsi¹¹, AnnaCarin Horne¹², Giovanni Filocamo², Helmut Wittkowski³, Marija Jelusic¹³, Jordi Anton¹⁴, Samira Khaldi-Plassart¹⁵, Alexandre Belot¹⁵, Gerd Horneff¹⁶, Seraina Palmer Sarrott¹⁷, Elvira Cannizzaro Schneider¹⁸, Lampros Fotis¹⁹, Pavla Dolezalova⁵, Angelo Ravelli²⁰, Seza Ozen⁷ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milano, Italy, ³Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Muenster, Germany, ⁴Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁵Centre for Paediatric Rheumatology and Autoinflammatory Diseases, Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, ⁶V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ⁸Department of Pediatrics, Division of Pediatric Pulmonology, Hacettepe University, Ankara, Turkey, ⁹Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ¹¹Department of Pediatrics and Rheumatology, IRRCS Istituto G. Gaslini, Genova, Italy, ¹²Department of pediatric rheumathology Karolinska University Hospital and Department of pediatrics, Karolinska Institute, Stockholm, Sweden, ¹³Department of Paediatrics, University of Zagreb School of Medicine, University Hospital Centre, Zagreb, Croatia, ¹⁴Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, ¹⁵Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France, ¹⁶Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁷Paediatric Rheumatology University Children’s Hospital Zurich, Zurich, Zurich, Switzerland, ¹⁸Paediatric Rheumatology University Children’s Hospital Zurich, Zurich, Switzerland, ¹⁹Pediatric Rheumatology Division, 3rd Department of Pediatrics, National and Kapodistrian University of Athens,‘’ATTIKON’’ General University Hospital, Athens, Greece, ²⁰IRRCS Istituto Giannina Gaslini and Università degli Studi di Genova, Genova, Italy
Background/Purpose: Chronic parenchymal lung disease (LD) is a new emerging severe life-threatening complication of sJIA. The number of sJIA patients with LD is apparently increasing…
Abstract Number: 135 • 2023 Pediatric Rheumatology Symposium
Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative
Dori Abel¹, Joyce Chang², Jon Burnham³, Chen Kenyon⁴ and Sabrina Gmuca⁵, ¹Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ²Boston Children's Hospital, Boston, MA, ³Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; PolicyLab, Children’s Hospital of Philadelphia, Philadelphia, PA; Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Center for Pediatric Clinical Effectiveness, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used…
Abstract Number: 097 • 2023 Pediatric Rheumatology Symposium
Survey of Covid-19 Immunization and Infection in Patients with Systemic Juvenile Idiopathic Arthritis and Adult Onset Still’s Disease
Mariana Correia Marques¹, Paul Subrata², Carol Lake³, Ly-Lan Bergeron⁴, Rashmi Sinha⁵, Luciana Peixoto⁶, Marinka Twilt⁷ and Michael Ombrello⁸, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases/Children`s National Hospital, Bethesda, MD, ²NIAID Collaborative Bioinformatics Resource (NCBR), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³NIH, GAITHERSBURG, MD, ⁴NIH/NIAMS, Vienna, VA, ⁵Systemic JIA Foundation, Cincinnati, OH, ⁶Systemic JIA Foundation, Cincinnati, ⁷Alberta Children's Hospital, Calgary, AB, Canada, ⁸Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, North Bethesda, MD
Background/Purpose: Immunization is one of the most important tools for the control of the Covid-19 pandemic. The safety and effectiveness of the Covid-19 immunizations have…
Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium
Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Je Hee Shin¹, Jung Yoon Pyo², Minkyung Han³, Myeongjee Lee³, Sung Min Lim¹, Jee Yeon Baek¹, Ji Young Lee¹, Ji-Man Kang¹, InKyung Jung³ and Jong Gyun Ahn¹, ¹Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ³Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…
Abstract Number: 102 • 2023 Pediatric Rheumatology Symposium
Preliminary Results from a Survey of Psychological Resilience Among JIA Patients
Daniella Schocken and Tracy Ting, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Psychological resilience – an individuals capacity to adapt in the face of stressors and recover after adverse events – has been linked to a…
Abstract Number: 003 • 2023 Pediatric Rheumatology Symposium
Inflammation or Infection? Understanding Linguistic and Cultural Nuances Impacting the Care of Somali Children with Juvenile Idiopathic Arthritis
Emily Hause, Abdirazak Ali and Muna Sunni, University of Minnesota, Minneapolis, MN
Background/Purpose: Data regarding the linguistic and cultural factors impacting the Somali patient experience and understanding with regards to juvenile idiopathic arthritis (JIA) are limited. We…
Abstract Number: 109 • 2023 Pediatric Rheumatology Symposium
Long-term Safety of Biologics versus Conventional Synthetic Treatments in Systemic Juvenile Idiopathic Arthritis Patients
Ana Isabel Rebollo-Giménez¹, Luca Carlini², Yulia Vyzhga³, Silvia Rosina⁴, Ekaterina Alexeeva⁵, Charlotte Myrup⁶, Silvia Magni Manzoni⁷, Maria Trachana⁸, Valda Stanevicha⁹, Constantin Ailioaie¹⁰, Elena Tsitsami¹¹, Alexis-Virgil Cochino¹², Chiara Pallotti¹³, Silvia Scala¹³, Angela Pistorio¹⁴, Sebastiaan Vastert¹⁵, Joost F. Swart¹⁶ and Nicolino Ruperto¹⁷, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Infiammatorie, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, ³IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattia Infiammatorie, Genova, Italy, ⁴IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁵Federal State Autonomous Institution “National Medical Research Center of Children's Health”, Ministry of Health of the Russian Federation, Moscow, Russia, ⁶Rigshospitalet, Pediatric rheumatology unit 4272, Copenhagem, Denmark, ⁷IRCCS Ospedale Pediatrico Bambino Gesù, Division of Rheumatology, Roma, Italy, ⁸Hippokration General Hospital, Thessaloniki University School of Medicine, First Department of pediatrics, Pediatric Immunology and Rheumatology Referral Center, Thessaloniki, Greece, ⁹Riga Stradins University, Children University Hospital, Riga, Latvia, ¹⁰Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ¹¹Aghia Sophia Childrens Hospital, First Department of Pediatrics, University of Athens Medical School, Athens, Greece, ¹²Institute for Mother and Child Care, Pediatrics, Bucharest, Romania, ¹³IRCCS Istituto Giannina Gaslini, U.O.C. Pediatric and Rheumatology Clinic, PRINTO, Genova, Italy, ¹⁴IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genova, Italy, ¹⁵Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, The Netherlands, Utrecht, Netherlands, ¹⁶Wilhelmina Children’s Hospital, Department of Pediatric Immunology and Rheumatology, Utrecht, Netherlands, ¹⁷IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, PRINTO, Genova, Italy
Background/Purpose: The better understanding of systemic Juvenile Idiopathic Arthritis (sJIA) pathogenesis and availability of new drugs, such as biologic disease-modifying anti-rheumatic drugs (bDMARDs) specifically dedicated…
Abstract Number: 016 • 2023 Pediatric Rheumatology Symposium
Gene Expression Changes in Polyarticular Juvenile Idiopathic Arthritis Following Tofacitinib Treatment
Esraa Eloseily¹, Alex Pickering², Sanjeev Dhakal³, Alexei Grom³, Hermine Brunner³ and Sherry Thornton⁴, ¹Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnti, OH, ²Department of Biomedical Informatics, Harvard Medical School, Boston, MA, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Despite advances in the understanding of juvenile idiopathic arthritis (JIA) pathophysiology, personalized treatments informed by gene transcriptomic profiles remain elusive. We aimed toexamine the…
Abstract Number: 113 • 2023 Pediatric Rheumatology Symposium
Proportion of Patients with a Polyphasic Disease Course in Systemic-onset Juvenile Idiopathic Arthritis May Be Higher in the Age of Cytokine Inhibitors
Itay Marmor¹, Rotem Semo Oz², Amir hendel³, Guy Hazan⁴, Kevin Baszis⁵, Anthony French⁵, Cuoghi Edens⁶, Irit Tirosh⁷, Yonatan Butbul Aviel⁸, Liora Harel⁹ and Gil Amarilyo¹⁰, ¹Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ²Sheba medical center, Herzelyia, Israel, ³Tel Aviv University, Tel Aviv, Israel, ⁴Soroka University Medical Center, Be'er Sheva, Israel, ⁵Washington University School of Medicine, St Louis, MO, ⁶University of Chicago, Chicago, IL, ⁷Sheba Medical Center, Savyon, Israel, ⁸Rambam Medical center, Haifa, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ¹⁰Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification…
Abstract Number: 017 • 2023 Pediatric Rheumatology Symposium
Potential Uveitic Biomarkers in Tears of Children with Juvenile Idiopathic Arthritis: A Pilot Study
Tiffany Nguyen¹, Ilaria Maccora¹, Mekibib Altaye¹, Wendy Haffey², Theresa Hennard¹, Alyssa Sproles¹, Sherry Thornton¹, Virginia Miraldi Utz¹, Ken Greis² and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²University of Cincinnati, Cincinnati, OH
Background/Purpose: Children diagnosed with oligoarticular juvenile idiopathic arthritis (JIA), the most commonly diagnosed subset of chronic arthritis, are at increased risk of developing uveitis. Known…
Abstract Number: 115 • 2023 Pediatric Rheumatology Symposium
Development of an Electronic Clinical Phenotype to Identify Potential Study Subjects with Juvenile Arthritis
Alysha Taxter¹, Marc Natter², Min-Lee Chang², Laura Schanberg³, Valarie Morrow⁴, Eveline Wu⁵, Tedryl Bumpass⁴, Alex Fist⁴, Meg Waite⁶, Vincent Del Gaizo⁷, Melanie Kohlheim⁷ and CARRA Registry Investigators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Boston Children's Hospital, Boston, MA, ⁷CARRA, Washington, DC
Background/Purpose: The LIMIT-JIA trial is the first study of the use of biologic therapy to prevent disease extension in children with newly diagnosed, uncomplicated, oligo-articular…
Abstract Number: 019 • 2023 Pediatric Rheumatology Symposium
Developing Standard Improvement Curves for Disease Activity, Pain and Quality of Life in Children with Newly Diagnosed Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Amieleena Chhabra¹, Matt Berkiwitz², Thomas Loughin², Lori Tucker³, Giles Boire⁴, Karine Toupin-April⁵, Dax Rumsey⁶, Michelle Batthish⁷, Linda Li⁸, Adam Huber⁹, Brian Feldman¹⁰, Jean-Phillippe Proulx-Gauthier¹¹, Ciaran Duffy¹², Paul Dancey¹³, Gordon Soon¹⁴, Heinrike Schmeling⁶ and Jaime Guzman¹⁵, ¹University of British Columbia, Vancouver, BC, Canada, ²Simon Fraser University, Burnaby, BC, Canada, ³BC Children's Hospital, Vancouver, BC, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵University of ottawa, Ottawa, ON, ⁶University of Alberta, Edmonton, AB, Canada, ⁷McMaster Children's Hospital, Hamilton, ON, Canada, ⁸Arthritis research, Vancouver, BC, Canada, ⁹University of Nova Scotia, Halifax, NS, Canada, ¹⁰Hospital for Sick Children / University of Toronto, Toronto, ON, Canada, ¹¹Université Laval, Québec, QC, Canada, ¹²Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ¹³Université de Montréal, Montreal, QC, Canada, ¹⁴University of Toronto, Toronto, ON, ¹⁵University of British Columbia, Vancouver, BC
Background/Purpose: When a diagnosis of juvenile idiopathic arthritis (JIA) is made, many parents are shocked to find out that arthritis occurs in children and may…

« Previous Page
1
…
7
8
9
10
11
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].